Hing Sheung Fung, MD
Rheumatology · Waco, TXNPI 1073624292
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $183,788 of the $265,712 with a category attached, or 69.2%. 47 manufacturers reported payments, led by Amgen at 31.5% of the total. Reporting peaked in 2019 at $60,108 and has fallen 64.5% since, to $21,358 in 2025. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,472 payments — averaging $180.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$84K
- Lilly USA, LLC$59K
- AstraZeneca$57K
- AbbVie$32K
- Aurinia Pharma U.S., Inc.$6K
- Johnson & Johnson$4K
- plus $24K from 41 others
Across 547 payments — averaging $2425.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$458K
- UCB SA$437K
- Janssen Research & Development, LLC$178K
- GSK$130K
- Amgen$38K
- Gilead$37K
- plus $48K from 5 others
What the payments were for
- Consulting fees$15,3076%
- Speaking & faculty fees$183,78869%
- Grants$2400%
- Travel & lodging$34,80913%
- Food & beverage$31,14912%
- Education$4200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$265,712 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 175 | $1,703,169 |
| RinvoqUpadacitinib | 133 | $918,568 |
| Orencia ClickjectAbatacept | 109 | $643,302 |
| Enbrel SureclickEtanercept | 75 | $587,083 |
| OrenciaAbatacept/Maltose | 111 | $540,466 |
| Skyrizi PenRisankizumab-Rzaa | 20 | $462,281 |
| Actemra ActpenTocilizumab | 101 | $442,454 |
| Cimzia (2 Pack)Certolizumab Pegol | 64 | $394,578 |
| Enbrel MiniEtanercept | 49 | $386,725 |
| ActemraTocilizumab | 93 | $380,007 |
| TremfyaGuselkumab | 28 | $376,890 |
| BenlystaBelimumab | 62 | $329,085 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $275,392 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 18 | $271,716 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $239,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $31,529 | $918,568133 claims |
| Johnson & JohnsonTremfya, Simponi Aria | $4,460 | $545,00450 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $1,493 | $540,466111 claims |
| UCB, Inc.Cimzia (2 Pack) | $3,374 | $394,57864 claims |
| Genentech, Inc.Actemra | $170 | $380,00793 claims |
| GSKBenlysta | $563 | $329,08562 claims |
| AmgenOtezla, Prolia, Evenity (2 Syringes) | $83,574 | $283,634105 claims |
| SanofiKevzara | $672 | $129,34930 claims |
| AstraZenecaSaphnelo | $57,308 | $108,76722 claims |
| Lilly USA, LLCOlumiant | $59,011 | $85,66231 claims |
| PfizerRuxience | $1,197 | $84,31611 claims |
| Radius Health, Inc.Tymlos | $275 | $30,23711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Waco
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.